A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: beta-Lactams; Ceftriaxone; Lactams

Criteria

Inclusion Criteria:

• male or female patients at least 18 years of age;

• hospitalization with community-acquired pneumonia or development of pneumonia within 48 hours of being hospitalized for another reason;

• fever;

• new or increased productive cough;

• chest pain, shortness of breath, or rapid breathing.

Exclusion Criteria:

• requiring intubation or ventilation;

• nursing home or extended care within 60 days before study;

• concomitant bacterial infection requiring antibiotics;

• long-term immunosuppressive therapy.